Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes.
Journal: Diabetes technology & therapeutics
Published: April 29, 2026
rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes.
Journal: European journal of endocrinology
Published: May 12, 2025
Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial.
Journal: JAMA network open
Published: February 14, 2025
Safety and Effectiveness of MiniMedTM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes.
Journal: Diabetes technology & therapeutics
Published: February 06, 2025
A Scalable Application of Artificial Intelligence-Driven Insulin Titration Program to Transform Type 2 Diabetes Management.
Journal: Diabetes technology & therapeutics
Published: March 07, 2024
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment.
Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Published: February 10, 2024
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Journal: Diabetes, obesity & metabolism
Published: December 13, 2023
Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism.
Journal: Journal of the Endocrine Society
Published: November 30, 2022
Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.
Journal: Diabetes, obesity & metabolism
Published: December 18, 2020
Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients.
Journal: Postgraduate medicine
Published: August 21, 2020
Clinical Use of IDegLira: Initiation to Titration After Basal Insulin.
Journal: Clinical diabetes : a publication of the American Diabetes Association
Published: January 25, 2020
Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).
Journal: Diabetes, obesity & metabolism
Published: December 23, 2019
Last Updated: 09/26/2026